News | January 07, 2025
Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara
The biosimilar Ustekinumab has been developed and manufactured by the company
The biosimilar Ustekinumab has been developed and manufactured by the company
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
